Abstract
Administration of specific drugs may occasionally induce acquired long QT syndrome (aLQTS), a disorder that predisposes to ventricular arrhythmias, typically of the torsade de pointes (TdP) type, and sudden cardiac death. “Forme fruste” mutations in congenital LQTS (cLQTS) genes have been reported repeatedly as the underlying cause of aLQTS, and are therefore considered as an important risk factor. We evaluated the impact of genetic susceptibility for aLQTS through mutations in cLQTS genes. Five cLQTS genes (KCNH2, KCNQ1, SCN5A, KCNE1, KCNE2) were thoroughly screened for genetic variations in 32 drug-induced aLQTS patients with confirmed TdP and 32 healthy individuals. Missense forme frust mutations were identified in four aLQTS patients: D85N in KCNE1 (two cases), T8A in KCNE2, and P347S in KCNH2. Three other missense variations were found both in patients and controls, and are thus unlikely to significantly influence aLQTS susceptibility. In addition, 13 silent and six intronic variations were detected, four of which were found in a single aLQTS patient but not in the controls. We conclude that missense mutations in the examined cLQTS genes explain only a minority of aLQTS cases.
Similar content being viewed by others
Abbreviations
- cLQTS :
-
Congenital long QT syndrome
- aLQTS :
-
Acquired long QT syndrome
- TdP :
-
Torsade de pointes
- ECG :
-
Electrocardiogram
- QTc :
-
Corrected QT
- PCR :
-
Polymerase chain reaction
- LD :
-
Linkage disequilibrium
References
Schwartz PJ, Moss AJ, Vincent GM, Crampton RS (1993) Diagnostic criteria for the long QT syndrome: an update. Circulation 88:782–784
Long QT database initiative of the Working Group on Arrhythmias of the European Society of Cardiologyhttp://pc4.fsm.it:81/cardmoc/
Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT (2000) Spectrum of mutations in Long-QT syndrome genes KvLQT1, HERG, SCN5A, KCNE1 and KCNE2. Circulation 102:1178–1185
Mohler PJ, Schott J-J, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V (2003) Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421:634–639
Lin JC, Quasney HA (1997) QT prolongation and development of torsade de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy 17:626–630
Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr (1990) Torsade de pointes occurring in association with terfenadine use. JAMA 264:2788–1790
Ikeda S, Oka H, Matunaga K Kubo S, Asai S, Miyahara Y, Osaka A, Kohno S (1998) Astemizole-induced torsade de pointes in a patient with vasospastic angina. Jpn Circ J 62:225-227
Makkar RR, Fromm BS, Steinmann RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 270:2590–2597
Kusano KF, Hata Y, Yumoto A, Emori T, Sato T, Ohe T (2001) Torsade de pointes with a normal QT interval associated with hypokalemia: a case report. Jpn Circ J 65: 757–760
Hsieh MH, Chen SA, Chiang CE, Tai CT, Lee SH, Wen ZC, Chang MS (1996) Drug-induced torsades de pointes in a patient with congenital long QT syndrome. Int J Cardiol 54:85–88
Moss AJ, Schwartz PJ (1982) Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias. Mod Concepts Cardiovasc Dis 51:85–90
Priori SG, Napolitano C, Schwartz PJ (1999) Low penetrance in the long QT syndrome. Clinical impact. Circulation 99:529–533
Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA (1999) MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175–187
Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL Jr, Goldstein SA (2000) A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 97:10613–10618
Chevalier P, Rodriguez C, Bontemps L, Miquel M, Kirkorian G, Rousson R, Potet F, Schott JJ, Baro I, Touboul P (2001) Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc Res 50:386–398
Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr, Roden DM (2002) Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105:1943–1948
Haverkamp W, Shenasa M, Borggrefe M, Breithardt G (1995) Torsades de Pointes. In: Zipes DP, Jalife J (eds) Cardiac electrophysiology - from cell to bedside, 2nd edn. Saunders, Philadelphia, pp 886–899
Itoh T, Tanaka T, Nagai R, Kikuchi K, Ogawa S, Okada S, Yamagata S, Yano K, Yazaki Y, Nakamura Y (1998) Genomic organization and mutational analysis of HERG, a gene responsible for familial long QT syndrome. Hum Genet 102:435–439
Splawski I, Shen J, Timothy KW, Vincent GM, Lehmann MH, Keating MT (1998) Genomic structure of three long QT syndrome genes: KVLQT1, HERG, and KCNE1. Genomics 51:86–97
Wang Q, Li Z, Shen J, Keating MT (1996) Genomic organization of the human SCN5A gene encoding the cardiac sodium channel. Genomics 34:9–16
Piquette RK (1999) Torsade de pointes induced by cisapride / clarithromycin interaction. Ann Pharmacother 33:22–26
Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, Acquaro G, Priori SG (2000) Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electr 11:691–696
Piippo K, Holmström S, Swan H, Viitasalo M, Raatikka M, Toivonen L, Kontula K (2001) Effect of the antimalarial drug halofantrine in the long QT syndrome due to a mutation of the cardiac sodium channel gene SCN5A. Am J Cardiol 87:909–911
Mohammad S, Zhou Z, Gong Q, January CT (1997) Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol Heart Circ Physiol 273:H2534–H2538
Wei J, Yang ICH, Tapper AR, Murray KT, Viswanathan P, Rudy Y, Bennett PB, Norris K, Balser JR, Roden DM, George ALJ (1999) KCNE1 polymorphism confers risk of drug-induced long-QT syndrome by altering kinetic properties of IKs potassium channels. Circulation 100:I495
Tesson F, Donger C, Denjoy I, Berthet M, Bennaceur M, Petit C, Coumel P, Schwarts K, Guicheney P (1996) Exclusion of KCNE1 (IsK) as a candidate gene for Jervell and Lange-Nielsen syndrome. J Mol Cell Cardiol 28:2051–2055
Iwasa H, Itoh T, Nagai R, Nakamura Y, Tanaka T (2000) Twenty single nucleotide polymorphisms (SNPs) and their allelic frequencies in four genes that are responsible for familial long QT in the Japanese population. J Hum Genet 45:182–183
Lai LP, Deng CL, Moss AJ, Kass RS, Liang CS (1994) Polymorphism of the gene encoding a human minimal potassium ion channel (minK). Gene 151:339–340
Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, Schwartz K, Coumel P, Guicheney P (1997) KvLQT1 C-terminal missense mutation causes forme fruste long QT syndrome. Circulation 96:2778–2781
Acknowledgements
We thank Rosemary Zvonar (Department of Pharmaceutical Services, The Ottawa Hospital, Canada) for providing a patient sample. E. Schulze-Bahr and W. Haverkamp are supported by grants from the Deutsche Forschungsgemeinschaft (grants Schu1082/2–2 and SFB556-A1) and the Fondation Leducq (France). P. Doevendans is supported by the Interuniversitary Cardiology Institute (The Netherlands).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paulussen, A.D.C., Gilissen, R.A.H.J., Armstrong, M. et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 82, 182–188 (2004). https://doi.org/10.1007/s00109-003-0522-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-003-0522-z